24 June 2020
Rutherford Health plc
Clinical Trials Collaboration with Panthera Biopartners
Rutherford Health plc (the "Company" or "Group" or "Rutherford") is delighted to announce that it has formed a collaboration with Panthera Biopartners Ltd ("Panthera"), an independent site management organisation (SMO).
Under the terms of the agreement, Rutherford will host clinical trials, organised by Panthera on behalf of its pharmaceutical and contract research organisation clients, of emerging cancer treatments at the Company's cancer centres in the UK.
The collaboration, called Panthera@theRutherford, combines Panthera's expertise in managing and running clinical trials with Rutherford's network of centres and leading oncologists.
Rutherford's network consists of four cancer treatment in Newport, Reading, Bedlington and Liverpool* and will draw patients from all over the UK offering Pharma and CROs access to patients through more than 170 referring oncologists.
Mike Moran, CEO Rutherford Health PLC commented: "We are delighted to partner with Panthera to undertake professional cancer research in our centres. We will be at the forefront of research into innovative therapies and we'll be able to offer more opportunities to patients and access to life-saving treatments."
Dr Ian Smith, Chief Medical Officer of Panthera, commented: "This really is a breakthrough partnership. Over 30% of all global clinical trials planned for 2020 are cancer trials; bringing research and cancer care together in one place will provide pharma and CROs the opportunity to undertake clinical trials with unrivalled access to more than 40 types of cancer and have access to potential patients when there is a great shortage of top-class sites."
* opening Summer 2020
The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
The directors of Rutherford Health plc accept responsibility for this announcement.